key: cord-0824624-d0p34gyn
authors: Trott, Klaus Rüdiger; Zschaeck, Sebastian; Beck, Marcus
title: Radiation therapy for COVID-19 pneumopathy
date: 2020-05-08
journal: Radiother Oncol
DOI: 10.1016/j.radonc.2020.05.003
sha: e08abf140dab53d471d0b7309a59a699bfc93ccd
doc_id: 824624
cord_uid: d0p34gyn

nan

The criticism expressed by Kirsch et al. of the two experimental in-vivo studies is valid. They really do not meet criteria of good experimental practice in radiation biology. The overall experimental design is flawed and the endpoints are poorly defined. Moreover, animal studies should rather be designed to provide quantitative insights into mechanisms of particular radiation effects.

The paper by Dhawan tries to do exactly this, arguing from the point of mechanisms of radiation action in inflammatory diseases [3] . Yet, this paper also has some weaknesses attributable to a rather selective quoting of experimental work, most of which has been going on in Germany since the mid 1980s. Most of those in-vivo experiments were performed using animal models of painful degenerative joint diseases. Such a model was also used in the one experimental study described in Dhawan's paper. Yet, pathogenesis, disease progression and treatment response of these popular models are not necessarily good models for the per-acute interstitial inflammation observed in severe COVID-19 acute respiratory syndrome. The in-vitro studies may be more relevant as most of them concentrate on specific pathways in the complex network of molecular signaling, leading from trigger to overt disease. A consistent finding in these experiments was a bi-phasic dose response relationship with anti-inflammatory effects at doses <1 Gy (maximum 0.5 Gy) and pro-inflammatory effects at doses >1 Gy (progressing with dose). A review of results of these studies is currently being published in Strahlentherapie und

A major problem of both papers is based on the fact that the majority of clinical applications of low-dose radiotherapy for acute and sub-acute inflammatory diseases were performed in the 1930s to 1970s in Germany, and mostly reported in German. The standard textbook on anti-inflammatory radiotherapy is written in German by Glauner with the title "Entzündungsbestrahlung" [4] .

Seegenschmidt et al. found out that even as late as in the 1980s, more than 50,000 patients per year were treated in Germany using low-dose radiotherapy for non-malignant diseases [5] . Yet, doses, timings and endpoints for treating COVID-19 pneumopathy cannot be generalised from these reports on sub-acute painful degenerative joint diseases. Information on mechanisms, dose Last but not least one has to keep in mind that experimental drugs used in COVID-19 patients can have serious side effects, including cardiac toxicity for Chloroquin [6] . We think that the two papers published in this issue point out, that careful selection of COVID-19 patients is a pivotal issue. Radiotherapy should probably be restricted to elderly patients progressing into critical illness.

Is low dose radiation therapy a potential treatment for COVID-19 pneumonia?

Lack of supporting data make the risks of a clinical trial of radiation therapy as a treatment for COVID-19 pneumonia unacceptable

Low Dose Radiation Therapy as a Potential Life Saving Treatment for COVID-19-induced Acute Respiratory Distress Syndrome (ARDS)

Die Entzündungs-Bestrahlung

Group on Radiotherapy for Non-malignant Diseases (GCG-BD). Radiotherapy for nonmalignant disorders: state of the art and update of the evidence-based practice guidelines

Use of Hydroxychloroquine and Chloroquine During the COVID-19 Pandemic: What Every Clinician Should Know